Watch: New Cancer Drugs from Artificial Life
In 2014 artificial life was made for the first time. Two new nucleotides were added—X and Y—to the standard four: A, G, T, C These new nucleotides allow for the addition of unnatural amino acids to create entirely new kinds of proteins. Now biotech company Synthorx has announced that they have developed a new cancer…
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Get featured
Want to get featured in MarketScale Healthcare?
Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.
In 2014 artificial life was made for the first time.
Two new nucleotides were added—X and Y—to the standard four: A, G, T, C
These new nucleotides allow for the addition of unnatural amino acids to create entirely new kinds of proteins.
Now biotech company Synthorx has announced that they have developed a new cancer drug using these artificial bacteria.
Interleukin-2 has been studied for decades as an immune system-stimulating cancer therapy, but it unfortunately comes with some serious side effects and is often unpredictable.
By adding an extra unnatural amino acid to Interleukin, Synthorx created a “Synthorin” that prolongs the protein’s activity while eliminating its immune-suppressing effects.
So, it turns out that creating artificial life is more than a cool laboratory trick—it may turn out to be a great new way to create new drugs as well.
Your experts belong here
Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.
Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.
